Table 4.
No. of Studies | AUC | Partial AUC | log DOR (95% CI) | DOR (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | +LR (95% CI) | −LR (95% CI) | Meta-Regression | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Sensitivity Z-value, P | Specificity Z-value, P | ||||||||||
Pooled miRNAs for Adenoma | 10 | 0.747 | 0.560 | 1.67 (1.27–2.07) | 5.31 (3.55–7.94) | 57.3% (40.8–72.3%) | 76.1% (66.1–89.4%) | 2.28 (1.84–2.84) | 0.53 (0.41–0.68) | — | — |
Sample size | |||||||||||
Small (Case n < 100) | 4 | 0.647 | 0.490 | 1.53 (0.86–2.20) | 6.36 (4.35–9.31) | 42.0% (27.5–58.1%) | 87.7% (70.0–95.6%) | 2.23 (1.93–2.57) | 0.35 (0.25–0.49) | −1.309 P < 0.001 | −2.011 P = 0.044 |
Large (Case n > 100) | 6 | 0.701 | 0.779 | 1.85 (1.47–2.23) | 4.63 (2.37–9.04) | 77.0% (67.7–84.2%) | 65.7% (70.5–85.9%) | 2.87 (1.71–4.83) | 0.71 (0.59–0.85) | ||
Pooled individual/Combination miRNAs | |||||||||||
Individual miRNA | 7 | 0.749 | 0.566 | 1.78 (1.26–2.30) | 5.93 (3.52–10.00) | 58.7% (41.6–73.9%) | 81.6% (63.6–91.8%) | 2.50 (1.86–3.36) | 0.52 (0.40–0.67) | −0.185 P = 0.853 | −0.194 P = 0.846 |
Combination miRNAs | 3 | 0.729 | 0.520 | 1.45 (0.73–1.17) | 4.26 (2.07–8.76) | 52.6% (13.4–88.8%) | 78.1% (42.2–94.5%) | 1.97 (1.45–2.67) | 0.55 (0.28–1.09) | ||
Quantitation method | |||||||||||
Absolute | 4 | 0.687 | 0.626 | 1.16 (0.84–1.47) | 3.18 (2.33–4.35) | 59.4% (48.0–69.9%) | 68.2% (36.7–52.0%) | 1.83 (1.54–2.16) | 0.61 (0.50–0.74) | −3.356 P = 0.001 | −1.859 P = 0.063 |
Relative | 6 | 0.802 | 0.622 | 2.12 (1.71–2.52) | 8.32 (5.55–12.48) | 56.9% (31.4–79.2%) | 86.7% (67.6–95.3%) | 3.01 (2.09–4.34) | 0.48 (0.31–0.73) |
AUC, Area under curve; DOR, Diagnostic odds ratio; +LR, Positive likelihood ratio; −LR, Negative likelihood ratio; Z-value, regression coefficient. P < 0.05 was considered as statistically significant.